Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Clinical impact of angiotensin I converting enzyme polymorphisms in subjects with resistant hypertension.

Imbalzano E, Vatrano M, Quartuccio S, Di Stefano R, Aragona CO, Mamone F, D'Ascola A, Scuruchi M, Felice F, Trapani G, Alibrandi A, Ciconte VA, Ceravolo R, Saitta A, Mandraffino G.

Mol Cell Biochem. 2017 Jun;430(1-2):91-98. doi: 10.1007/s11010-017-2957-5. Epub 2017 Feb 11.

PMID:
28190172
2.

Arterial stiffness as a predictor of recovery of left ventricular systolic function after acute myocardial infarction treated with primary percutaneous coronary intervention.

Imbalzano E, Vatrano M, Mandraffino G, Ghiadoni L, Gangemi S, Bruno RM, Ciconte VA, Paunovic N, Costantino R, Mormina EM, Ceravolo R, Saitta A, Dattilo G.

Int J Cardiovasc Imaging. 2015 Dec;31(8):1545-51. doi: 10.1007/s10554-015-0733-8. Epub 2015 Aug 4.

PMID:
26239135
3.

A quick bailout ongoing of cardiogenic shock and iatrogenic dissection of the left main coronary artery.

Vatrano M, Dattilo G, Mandraffino G, Gangemi S, Ciconte VA, Quartuccio S, Ceravolo R, Imbalzano E.

Int J Cardiol. 2015 Apr 1;184:473-4. doi: 10.1016/j.ijcard.2015.03.001. Epub 2015 Mar 3. No abstract available.

PMID:
25756567
4.

Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies.

Omboni S, Malacco E, Mallion JM, Volpe M, Zanchetti A; Study Group.

J Hypertens. 2012 Jul;30(7):1468-77. doi: 10.1097/HJH.0b013e32835466ac.

PMID:
22573127
5.

Valsartan for prevention of recurrent atrial fibrillation.

GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G.

N Engl J Med. 2009 Apr 16;360(16):1606-17. doi: 10.1056/NEJMoa0805710. Erratum in: N Engl J Med. 2009 May 28;360(22):2379.

6.

Effect of dronedarone on cardiovascular events in atrial fibrillation.

Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators.

N Engl J Med. 2009 Feb 12;360(7):668-78. doi: 10.1056/NEJMoa0803778. Erratum in: N Engl J Med. 2009 Jun 4;360(23):2487. N Engl J Med. 2011 Apr 14;364(15):1481.

7.

Overdrive versus conventional or closed-loop rate modulation pacing in the prevention of atrial tachyarrhythmias in Brady-Tachy syndrome: on behalf of the Burden II Study Group.

Puglisi A, Favale S, Scipione P, Melissano D, Pavia L, Ascani F, Elia M, Scaccia A, Sagone A, Castaldi B, Musacchio E, Botto GL; Burden II Study Group.

Pacing Clin Electrophysiol. 2008 Nov;31(11):1443-55. doi: 10.1111/j.1540-8159.2008.01208.x.

PMID:
18950302
8.

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators.

N Engl J Med. 2003 Nov 13;349(20):1893-906. Epub 2003 Nov 10. Erratum in: N Engl J Med. 2004 Jan 8;350(2):203.

9.

[Supraventricular tachycardia in children].

Battaglia T, Paparo F, Fumarulo A, Attanà A, Ciconte V, Caristo S, Primerano, Martini B.

Minerva Med. 1983 Dec 15;74(47-48):2887-91. Italian.

PMID:
6657130

Supplemental Content

Loading ...
Support Center